Skip to main content
AkademIndex

Products

For developers

AkademBaseOpen API for the ecosystem
← Back to work

Works cited by this work

47 works

Work: Personalized rosuvastatin therapy in problem patients with partial statin intolerance

  1. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins

    Colin Baigent, Anthony Keech, Patricia M. Kearney +8

    Review article20056 citations
    ABI

  2. <i>SLCO1B1</i> Variants and Statin-Induced Myopathy — A Genomewide Study

    The SEARCH Collaborative Group

    Article20083 citations
    ABI

  3. Lipid-lowering response to statins is affected by CYP3A5 polymorphism

    Kari T. Kivistö, Mikko Niemi, Elke Schaeffeler +6

    Article20043 citations
    ABI

  4. Pharmacogenomics — Drug Disposition, Drug Targets, and Side Effects

    William E. Evans, Howard L. McLeod

    Article20033 citations
    ABI

  5. Effect of Polymorphic <i>CYP3A5</i> Genotype on the Single‐Dose Simvastatin Pharmacokinetics in Healthy Subjects

    Kyoung‐Ah Kim, Pil‐Whan Park, Ock‐Je Lee +2

    Article20063 citations
    ABI

  6. Comprehensive efforts to increase adherence to statin therapy

    Alexander Vonbank, Stefan Agewall, Keld Per Kjeldsen +13

    Article20163 citations
    ABI

  7. <i>CYP3AP1*3</i>Allele Is Associated With Lipid-Lowering Efficacy of Simvastatin and Atorvastatin in Chinese Women

    Yanpeng Li, Lirong Zhang, Min Jia +1

    Article20102 citations
    ABI

  8. The role of common variants of ABCB1, CYP3A4, and CYP3A5 genes in lipid-lowering efficacy and safety of simvastatin treatment

    Marilu Fiegenbaum, F DASILVEIRA, C VANDERSAND +4

    Article20052 citations
    ABI

  9. Metabolism, excretion, and pharmacokinetics of rosuvastatin in healthy adult male volunteers

    Paul Martin, Mike J. Warwick, Aaron Dane +4

    Article20032 citations
    ABI

  10. CYP3A4*22 and CYP3A5*3 are associated with increased levels of plasma simvastatin concentrations in the cholesterol and pharmacogenetics study cohort

    Joseph P. Kitzmiller, Jasmine A. Luzum, Damiano Baldassarre +2

    Article20142 citations
    ABI

  11. Novel CYP3A4 intron 6 single nucleotide polymorphism is associated with simvastatin-mediated cholesterol reduction in The Rotterdam Study

    Laure Elens, Matthijs L. Becker, Vincent Haufroid +5

    Article20112 citations
    ABI

  12. CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12: Evidence for an allelic variant with altered catalytic activity

    Fumihiro Sata

    Article20002 citations
    ABI

  13. Needed: Pragmatic Clinical Trials for Statin-Intolerant Patients

    Patricia D. Maningat, Jan L. Breslow

    Article20112 citations
    ABI

  14. Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs

    Daqing Wang, Yingying Guo, Steven Wrighton +2

    Article20102 citations
    ABI

  15. Statin-associated muscle symptoms: impact on statin therapy—European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management

    Erik S.G. Stroes, Paul D. Thompson, Alberto Corsini +37

    Review article20152 citations
    ABI

  16. SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid

    Marja K. Pasanen, Mikko Neuvonen, Pertti J. Neuvonen +1

    Article20062 citations
    ABI

  17. Untitled

    Other1 citations
    ABI

  18. Untitled

    Other1 citations
    ABI

  19. Untitled

    Other1 citations
    ABI

  20. Untitled

    Other1 citations
    ABI

  21. Untitled

    Other1 citations
    ABI

  22. Untitled

    Other1 citations
    ABI

  23. Untitled

    Other1 citations
    ABI

  24. Untitled

    Other1 citations
    ABI

  25. Untitled

    Other1 citations
    ABI